



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Refine Search

Search Results -

Term	Documents
13Q14	237
13Q14S	0
VECTOR	402532
VECTORS	211704
(13Q14 SAME VECTOR).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5
((13Q14) SAME (VECTOR)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L6

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Sunday, November 05, 2006 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name
side by side

Query**Hit Count**

**Set
Name**
result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;
OP=AND

<u>L6</u>	(13q14) same (vector)	5	<u>L6</u>
<u>L5</u>	L3 not L4	3	<u>L5</u>
<u>L4</u>	L3 and (prostate)	7	<u>L4</u>
<u>L3</u>	(miR15) and (cancer or tumor)	10	<u>L3</u>
<u>L2</u>	L1 and miR15	2	<u>L2</u>

L1

Croce-Carlo.in.

13

L1

END OF SEARCH HISTORY

Welcome to DialogClassic Web(tm)

Dialog level 05.12.03D
Last logoff: 03nov06 17:33:53
Logon file001 05nov06 11:37:38

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***Verdict Market Research (File 769)
***EMCare (File 45)
***Trademarkscan - South Korea (File 655)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***Files 173 & 973, Adis Clinical Trials Insight
***File 11, PsycInfo
***File 531, American Business Directory
*** The 2005 reload of the CLAIMS files (Files 340, 341, 942)
is now available online.

DATABASES REMOVED

***File 196, FINDEX
***File 468, Public Opinion Online (POLL)
Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/95
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus
(File 302).

>>>For the latest news about Dialog products, services, content<<<
>>>and events, please visit What's New from Dialog at <<<
>>><http://www.dialog.com/whatsnew/>. You can find news about<<<
>>>a specific database by entering HELP NEWS <file number>.<<<
>>>PROFILE is in a suspended state.
>>>Contact Dialog Customer Services to re-activate it.
* * *

File 1:ERIC 1966-2006/Oct
(c) format only 2006 Dialog

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

Cost is in DialUnits
?

B 155, 159, 5, 73
05nov06 11:37:51 User259876 Session D940.1
\$0.82 0.233 DialUnits File1
\$0.82 Estimated cost File1
\$0.05 INTERNET
\$0.87 Estimated cost this search
\$0.87 Estimated total session cost 0.233 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2006/Nov 03
(c) format only 2006 Dialog
File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog
*File 159: Cancerlit is no longer updating.
Please see HELP NEWS159.

File 5:Biosis Previews(R) 1969-2006/Oct W5
 (c) 2006 The Thomson Corporation
 File 73:EMBASE 1974-2006/Nov 03
 (c) 2006 Elsevier B.V.

Set	Items	Description
---	-----	-----

?

S (MIR15) AND (CANCER OR TUMOR)

7 MIR15
 2808991 CANCER
 2774265 TUMOR

S1 6 (MIR15) AND (CANCER OR TUMOR)

?

RD

S2 2 RD (unique items)

?

T S2/3,K/ALL

2/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

15446476 PMID: 15648093

miR-15a and miR-16-1 down-regulation in pituitary adenomas.

Bottoni Arianna; Piccin Daniela; Tagliati Federico; Luchin Andrea;
 Zatelli Maria Chiara; degli Uberti Ettore C

Section of Endocrinology, Department of Biomedical Sciences and Advanced
 Therapies-University of Ferrara, Ferrara, Italy.

Journal of cellular physiology (United States) Jul 2005, 204 (1)
 p280-5, ISSN 0021-9541--Print Journal Code: 0050222

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... and a lower p43 secretion, suggesting that these genes may, at least
 in part, influence tumor growth. (c) 2004 Wiley-Liss, Inc.

2/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

14033203 PMID: 12434020

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Calin George Adrian; Dumitru Calin Dan; Shimizu Masayoshi; Bichi Roberta;
 Zupo Simona; Noch Evan; Aldler Hansjuerg; Rattan Sashi; Keating Michael;
 Rai Kanti; Rassenti Laura; Kipps Thomas; Negrini Massimo; Bullrich
 Florencia; Croce Carlo M

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
 19107, USA.

Proceedings of the National Academy of Sciences of the United States of
 America (United States) Nov 26 2002, 99 (24) p15524-9, ISSN 0027-8424
 --Print Journal Code: 7505876

Contract/Grant No.: P01CA76259; CA; NCI; P01CA81534; CA; NCI; P30CA56036;
 CA; NCI
 Publishing Model Print-Electronic
 Document type: Journal Article
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: MEDLINE; Completed

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

... Dicer, a ribonuclease that recognizes target mRNAs via base-pairing interactions. Here we show that miR15 and miR16 are located at chromosome 13q14, a region deleted in more than half of B cell chronic lymphocytic leukemias (B-CLL). Detailed deletion and expression analysis shows that miR15 and miR16 are located within a 30-kb region of loss in CLL, and that...

...; Gov't, P.H.S.; Reverse Transcriptase Polymerase Chain Reaction; Tonsil--cytology--CY; Transcription, Genetic; Tumor Cells, Cultured --chemistry--CH; Tumor Stem Cells--chemistry--CH
 ?

Set	Items	Description
S1	6	(MIR15) AND (CANCER OR TUMOR)
S2	2	RD (unique items)

?

S (13Q14) (S) (VECTOR)
 2992 13Q14
 333087 VECTOR
 S3 11 (13Q14) (S) (VECTOR)
 ?

RD
 S4 5 RD (unique items)
 ?

T S4/3,K/ALL

4/3,K/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2006 Dialog. All rts. reserv.

07167511: PMID: 2877932

A straightforward approach to isolate DNA sequences with potential linkage to the retinoblastoma locus.

Scheffer H; van der Lelie D; Aanstoot G H; Goor N; Nienhaus A J; van der Hout A H; Pearson P L; Buys C H

Human genetics (GERMANY, WEST) Nov 1986, 74 (3) p249-55, ISSN 0340-6717--Print Journal Code: 7613873

Publishing Model Print
 Document type: Journal Article
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: MEDLINE; Completed

...11.9-17.2 kb) from the cell hybrid were inserted into the lambda phage vector EMBL4. From eleven recombinants having a human insert thirteen putative unique DNA sequences were isolated and cloned into the plasmid vector pBR329. A human-mouse hybrid containing a human chromosome 13 with

a deletion of 13q14 and lacking its undeleted homologue was constructed to be used in a selection procedure for...

... sequences belonging to band q14. Three probes originating from two different phages were assigned to 13q14 because they did not hybridise to DNA from this cell hybrid. One of these 13q14 probes detects a low frequency (2/44) MspI restriction fragment length polymorphism. The probes are...

4/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

06546779 PMID: 6210139

Isolation of human chromosome 13-specific DNA sequences cloned from flow sorted chromosomes and potentially linked to the retinoblastoma locus.

Lalande M; Dryja T P; Schreck R R; Shipley J; Flint A; Latt S A

Cancer genetics and cytogenetics (UNITED STATES) Dec 1984, 13 (4)
p283-95, ISSN 0165-4608--Print Journal Code: 7909240

Contract/Grant No.: HD 04807/18658-02; HD; NICHD

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... recombinant DNA library has been constructed using flow sorted chromosome #13 DNA and the phage vector, Charon 21A. Roughly 90% of the phage inserts in the library hybridize to human repetitive...

...Southern blot analysis of the DNA of a retinoblastoma patient exhibiting a deletion of band 13q14 and of karyotypically normal individuals, two phage inserts have been putatively assigned to band 13q14, the currently accepted locus for a genetic determinant for retinoblastoma. These two DNA probes show...

4/3,K/3 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0015837483 BIOSIS NO.: 200600182878

Gene expression profiling of myeloma cells at diagnosis can predict response to therapy with thalidomide and dexamethasone combination.

AUTHOR: Kumar Shaji (Reprint); Greipp Philip R; Haug Jessica; Kline Michael
; Chng Wee Joo; Blood Emily; Bergsagel Leif; Lust John A; Gertz Morie A;
Fonseca Rafael; Rajkumar S Vincent

AUTHOR ADDRESS: Mayo Clin, Rochester, MN USA**USA

JOURNAL: Blood 106 (11, Part 1): p152A NOV 16 2005 2005

CONFERENCE/MEETING: 47th Annual Meeting of the

American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;
20051210

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: response to the thalidomide Dexamethasone therapy. Using the

class prediction tool available in Genespring (Support Vector Machines), we identified 25 genes that reliably predicted non responders (PD, NC) from the responders...
 ...response) for the purpose of tailoring therapy to the patient.[GRAPHICS]presence of a del(13q14) either in a subclone (< 60% of analyzed nuclei) or major clone had no significant influence...

4/3,K/4 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
 (c) 2006 The Thomson Corporation. All rts. reserv.

0014379373 BIOSIS NO.: 200300336116

Stable Transfection of Human Multiple Myeloma Cell Lines (HMMCL) with the Candidate Chromosome 13 Tumor Suppressor Gene (TSG) TGF-beta Stimulated Clone (TSC-22) Results in Dramatic Morphologic, Phenotypic and Gene Expression Changes.

AUTHOR: Tian Erming (Reprint); Verma Monica (Reprint); Xiao Yan (Reprint); Derrick Jena (Reprint); Zhan Fenghuang (Reprint); Shaughnessy John (Reprint)

AUTHOR ADDRESS: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA**USA

JOURNAL: Blood 100 (11): pAbstract No. 1516 November 16, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10; 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: represents the most ominous prognostic variable in this disease. We have previously shown that the 13q14 region is the minimally deleted region and represents the most likely site of a putative...

...have also reported that TSC-22, a highly conserved leucine zipper transcription repressor located at 13q14, is the only gene that is extinguished in a significant proportion of MM PC with...

...further investigate the role of TSC-22 loss in MM we created a mammalian expression vector that expresses both TSC-22 and green fluorescence protein (GFP) or GFP alone. We have...

4/3,K/5 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
 (c) 2006 The Thomson Corporation. All rts. reserv.

0013145733 BIOSIS NO.: 200100317572

Deletions of 17p13.1 and 13q14 are rare in Waldenstrom's macroglobulinemia clonal cells

AUTHOR: Schop Roelandt F J (Reprint); Jalal Syed M; Van Wier Scott A (Reprint); Ahmann Gregory J (Reprint); Bailey Richard J (Reprint); Yusuf Rushidia Z (Reprint); Rajkumar S Vincent (Reprint); Dispenzieri Angela (Reprint); Lacy Martha Q (Reprint); Lust John A (Reprint); Witzig Thomas E (Reprint); Gertz Morie A (Reprint); Greipp Philip R (Reprint); Kyle Robert A (Reprint); Fonseca Rafael (Reprint)

AUTHOR ADDRESS: Hematology, Mayo Clinic, Rochester, MN, USA**USA

JOURNAL: Blood 96 (11 Part 1): p372a November 16, 2000 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: over 5 years. Deletions of the p53 genomic region (chromosome 17p13.1) and deletions of 13q14 have both been associated with advanced stages of the plasma cell dyscrasias and with a...

...method (Miltenyi Biotech). We performed double color cIg-FISH utilizing an anti-IgM AMCA antibody (Vector Laboratories). To test for 13q14 deletions we used the probes LSI 13 (which includes Rb) and D13S319 (Vysis, Inc.). To...

...We attempted to score at least 100 cells per patient. Fifteen patients were studied for 13q14 deletions and two (13%) were found to be abnormal in 53 and 96% of the...

?

Set	Items	Description
S1	6	(MIR15) AND (CANCER OR TUMOR)
S2	2	RD (unique items)
S3	11	(13Q14) (S) (VECTOR)
S4	5	RD (unique items)

?

S (MICRORNA) (S) (TREATMENT OR THERAPY)	
	2161 MICRORNA
	5714123 TREATMENT
	6464643 THERAPY
S5	28 (MICRORNA) (S) (TREATMENT OR THERAPY)

?

RD	
S6	18 RD (unique items)

?

S S6 AND (CANCER OR PROSTATE)	
	18 S6
	2808991 CANCER
	275882 PROSTATE
S7	7 S6 AND (CANCER OR PROSTATE)

?

T S7/3,K/ALL

7/3,K/1 (Item 1 from file: 155)
 DIALOG(R)File 155:MEDLINE(R)
 (c) format only 2006 Dialog. All rts. reserv.

21889304 PMID: 17060945

MicroRNA signatures in human cancers.

Calin George A; Croce Carlo M

Department of Molecular Virology, Immunology and Medical Genetics and

Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA.

Nature reviews. Cancer (England) Nov 2006, 6 (11) p857-66, ISSN 1474-175X--Print Journal Code: 101124168

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

MicroRNA (miRNA) alterations are involved in the initiation and progression of human cancer. The causes of the widespread differential expression of miRNA genes in malignant compared with normal cells can be explained by the location of these genes in cancer-associated genomic regions, by epigenetic mechanisms and by alterations in the miRNA processing machinery. MiRNA...

... of human tumours has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment. In addition, profiling has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer.

7/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

21042713 PMID: 16512781

Molecular profiling of cervical neoplasia.

Martin Cara M; Astbury Katharine; O'Leary John J

Department of Pathology, Coombe Women's Hospital, Dublin 8, Ireland.
cara.martin@tcd.ie

Expert review of molecular diagnostics (England) Mar 2006, 6 (2) p217-29, ISSN 1744-8352--Electronic Journal Code: 101120777

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Cervical cancer, a potentially preventable disease, remains the second most common malignancy in women worldwide. Human papillomavirus is the single most important etiological agent in cervical cancer, contributing to neoplastic progression through the action of viral oncoproteins, mainly E6 and E7, which...

... malignant changes and that other host genetic variations are important in the development of cervical cancer. This article will discuss the latest molecular profiling techniques available and review the published literature relating to their role in the diagnosis and management of cervical dysplasia and cancer. It is hoped that these techniques will allow the detection of novel biomarkers at DNA, RNA, microRNA and protein levels, which may ultimately play a role in facilitating early disease diagnosis and in predicting response to therapies, thus allowing the development of personalized treatment strategies.

7/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

15622772 PMID: 16251535

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Calin George Adrian; Ferracin Manuela; Cimmino Amelia; Di Leva Gianpiero; Shimizu Masayoshi; Wojcik Sylwia E; Iorio Marilena V; Visone Rosa; Sever Nurettin Ilfer; Fabbri Muller; Iuliano Rodolfo; Palumbo Tiziana; Pichiorri Flavia; Roldo Claudia; Garzon Ramiro; Sevignani Cinzia; Rassenti Laura; Alder Hansjuerg; Volinia Stefano; Liu Chang-gong; Kipps Thomas J; Negrini Massimo; Croce Carlo M

Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA.

New England journal of medicine (United States) Oct 27 2005, 353 (17) p1793-801, ISSN 1533-4406--Electronic Journal Code: 0255562

Contract/Grant No.: P01CA76259; CA; NCI; P01CA81534; CA; NCI; P30CA56036; CA; NCI

Publishing Model Print; Comment in N Engl J Med. 2005 Oct 27;353(17) 1768-71; Comment in PMID 16251533

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

BACKGROUND: MicroRNA expression profiles can be used to distinguish normal B cells from malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated whether microRNA profiles are associated with known prognostic factors in CLL. **METHODS:** We evaluated the microRNA expression profiles of 94 samples of CLL cells for which the level of expression of...

... immunoglobulin heavy-chain variable-region (IgV(H)) gene, and the time from diagnosis to initial treatment were known. We also investigated the genomic sequence of 42 microRNA genes to identify abnormalities. **RESULTS:** A unique microRNA expression signature composed of 13 genes (of 190 analyzed) differentiated cases of CLL with low...

... levels and cases with unmutated IgV(H) from those with mutated IgV(H) . The same microRNA signature was also associated with the presence or absence of disease progression. We also identified...

... mutation in the miR-16-1-miR-15a primary precursor, which caused low levels of microRNA expression in vitro and in vivo and was associated with deletion of the normal allele...

... of 75 patients with CLL, but no such mutations were found in 160 subjects without cancer (P<0.001). **CONCLUSIONS:** A unique microRNA signature is associated with prognostic factors and disease progression in CLL. Mutations in microRNA transcripts are common and may have functional importance. Copyright 2005 Massachusetts Medical Society.

7/3,K/4 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13815031 EMBASE No: 2006243348

MicroRNAs as a potential magic bullet in cancer

Slack F.J.; Weidhass J.B.

F.J. Slack, Yale University, Department of Molecular Cellular and Developmental Biology, PO Box 208103, New Haven, CT 06520 United States

AUTHOR EMAIL: frank.slack@yale.edu
Future Oncology (FUTURE ONCOL.) (United Kingdom) 2006, 2/1 (73-82)
ISSN: 1479-6694 eISSN: 1744-8301
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 90

MicroRNAs as a potential magic bullet in cancer

Genes that control cell differentiation and development are frequently mutated in human cancer. Micro (mi)RNAs are small regulatory RNAs that are emerging as important regulators of cell division/differentiation and human cancer genes. In this review, the miRNA cancer connection is discussed and the possibility of using this novel, but potentially powerful new therapy, involving miRNAs, to treat cancers is speculated on. For example, lung cancer is the major cause of cancer deaths in the USA, but existing therapies fail to treat this disease in the overwhelming...

...oncomirs', natural miRNA tumor suppressors in lung tissue, which may prove useful in treating lung cancer or enhancing current treatments for lung cancer. (c) 2006 Future Medicine Ltd.

DRUG DESCRIPTORS:

*microRNA--drug development--dv; * microRNA --drug therapy --dt; *microRNA --endogenous compound--ec; *microRNA--pharmaceutics--pr; *microRNA --pharmacology--pd

MEDICAL DESCRIPTORS:

* cancer genetics
gene control; cell differentiation; cell maturation; mutational analysis; regulatory mechanism; cell division; cancer mortality; United States; lung cancer --drug therapy--dt; lung cancer --prevention--pc; treatment failure; RNA interference; developmental stage; Caenorhabditis elegans; gene amplification; upregulation; gene expression...

...dr; malignant neoplastic disease--drug therapy--dt; malignant neoplastic disease--radiotherapy--rt; drug mechanism; pancreas cancer --drug therapy --dt; human; nonhuman; review; priority journal

SECTION HEADINGS:

016 Cancer
022 Human Genetics
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
039 Pharmacy

7/3,K/5 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13800586 EMBASE No: 2006229357

Small RNAs and non-small cell lung cancer

Tong A.W.

Dr. A.W. Tong, Cancer Immunology Research Laboratory, Baylor-Sammons Cancer Center, 3500 Gaston Avenue, Dallas, TX 75246 United States

AUTHOR EMAIL: alex.t@baylorhealth.edu

Current Molecular Medicine (CURR. MOL. MED.) (Netherlands) 2006, 6/3 (339-349)

CODEN: CMMUB ISSN: 1566-5240

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 124

Small RNAs and non-small cell lung cancer

Patients with non-small cell lung cancer (NSCLC) are commonly diagnosed with advanced disease and have limited therapeutic options. Experimental treatment approaches...

...is susceptible to molecular perturbations. RNA interference (RNAi) has generated considerable excitement as a potential cancer therapeutic application. RNAi is the process by which small, double stranded RNA molecules (small interfering RNA, or siRNA) can initiate sequence-specific, post-transcriptional gene silencing (PTGS). Cancer growth inhibition was attained through siRNA-knockdown of unique or overexpressed cancer oncogenetic messages that are relevant to NSCLC pathophysiology. As with other loss-of-function cancer gene therapy approaches, clinical efficacy of siRNA depends largely on the extent of cell target...

...viral delivery may have more immediate relevance due to its wider clinical acceptance in the cancer gene therapy arena. We advocate the use of conditional replicative, oncolytic adenovirus; for siRNA delivery...

DRUG DESCRIPTORS:

tumor vaccine--drug therapy--dt; liposome--pharmaceutics--pr; microRNA --drug comparison--cm; microRNA --drug therapy --dt; microRNA --pharmaceutics--pr; microRNA--pharmacology--pd; cisplatin--drug combination--cb; cisplatin--drug therapy--dt...

MEDICAL DESCRIPTORS:

*lung non small cell cancer --drug therapy--dt; *lung non small cell cancer --epidemiology--ep; *lung non small cell cancer --etiology--et; *lung non small cell cancer --prevention--pc; *lung non small cell cancer --surgery--su; *RNA interference vaccination; viral gene therapy; tumor regression; posttranscriptional gene silencing; cancer inhibition; antineoplastic activity; gene overexpression; drug efficacy; drug targeting; viral gene delivery system; adenovirus vector; drug safety; virus infectivity; cancer survival; lung surgery; drug response; drug half life; retrovirus vector; drug accumulation; drug tissue level...

SECTION HEADINGS:

- 015 Chest Diseases, Thoracic Surgery and Tuberculosis
- 016 Cancer
- 022 Human Genetics
- 037 Drug Literature Index
- 038 Adverse Reaction Titles
- 039 Pharmacy

7/3,K/6 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

13671124 EMBASE No: 2006159411

Webcast video editorials - Breakthrough in silencing "bad" genes

Komaroff A.L.

Dr. A.L. Komaroff, Department of Medicine, Harvard Medical School, Boston, MA United States

AUTHOR EMAIL: komaroff@hms.harvard.edu

MedGenMed Medscape General Medicine (MEDGENMED MEDSCAPE GEN. MED.) (United States) 2006, 8/1 (2p)

CODEN: MMGMC ISSN: 1531-0132

ARTICLE NUMBER: 88

DOCUMENT TYPE: Journal ; Editorial

LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 2

DRUG DESCRIPTORS:

messenger RNA--endogenous compound--ec; microRNA --drug therapy --dt;
cholesterol--endogenous compound--ec

MEDICAL DESCRIPTORS:

...herpes--etiology--et; virus hepatitis--etiology--et; Retrovirus
infection--etiology--et; spinocerebellar degeneration--etiology--et;
cancer therapy; retina macula degeneration--drug therapy--dt; immune
system; gene transfer; gene delivery system; intracellular...

SECTION HEADINGS:

004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
008 Neurology and Neurosurgery
016 Cancer
022 Human Genetics
026 Immunology, Serology and Transplantation
037 Drug Literature Index

7/3,K/7 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier B.V. All rts. reserv.

12977172 EMBASE No: 2005036915

12th Annual Congress of the European Society of Gene Therapy

Read M.L.; Spice R.; Parker A.L.; Mir S.; Logan A.

Dr. M.L. Read, University of Birmingham, Wolfson Research Laboratories,
Division of Medical Sciences, Birmingham, B15 2TH United Kingdom

AUTHOR EMAIL: m.l.read.20@bham.ac.uk

Expert Opinion on Biological Therapy (EXPERT OPIN. BIOL. THER.) (United
Kingdom) 2005, 5/1 (137-141)

CODEN: EOBT A ISSN: 1471-2598

DOCUMENT TYPE: Journal ; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 10

The 2004 European Society of Gene Therapy (ESGT) meeting took place at
Tampere Hall in Finland and highlighted advances in a variety of topics,
including cancer , zinc-fingers, stem cells, small interfering RNA
(siRNA), microRNA , and recent developments of non-viral and viral
vectors. This meeting was attended by 513...

...One of the aims of this meeting was to take a critical look at gene
therapy and the prospects for the future. Several presentations reported
on RNA-based technologies, such as...

...functional genes involved in biological phenotypes. Critical assessments
were made of other aspects of gene therapy , such as genome editing and
the use of protein transduction domains (PTDs) in gene- and...

...vectors were also important areas of discussion, especially following
details released by the UK Gene Therapy Advisory Committee of perhaps the
first known case of lentiviral vector-associated oncogenesis. Finally,
updates...

MEDICAL DESCRIPTORS:

...vector; medical research; RNA interference; phenotype; gene library;
genome; protein domain; safety; lentivirus vector; carcinogenesis; cancer
therapy; survival; tumor suppressor gene; cancer --drug therapy--dt;
glioblastoma--drug therapy--dt; Newcastle disease paramyxovirus; adenovirus

vector; human; nonhuman; clinical...

?

Set	Items	Description
S1	6	(MIR15) AND (CANCER OR TUMOR)
S2	2	RD (unique items)
S3	11	(13Q14) (S) (VECTOR)
S4	5	RD (unique items)
S5	28	(MICRORNA) (S) (TREATMENT OR THERAPY)
S6	18	RD (unique items)
S7	7	S6 AND (CANCER OR PROSTATE)

?

COST

05nov06 11:42:40 User259876 Session D940.2

\$1.73 0.509 DialUnits File155

\$1.54 7 Type(s) in Format 3

\$1.54 7 Types

\$3.27 Estimated cost File155

\$0.24 0.076 DialUnits File159

\$0.24 Estimated cost File159

\$2.14 0.357 DialUnits File5

\$6.60 3 Type(s) in Format 3

\$6.60 3 Types

\$8.74 Estimated cost File5

\$7.36 0.657 DialUnits File73

\$12.40 4 Type(s) in Format 3

\$12.40 4 Types

\$19.76 Estimated cost File73

OneSearch, 4 files, 1.599 DialUnits FileOS

\$1.33 INTERNET

\$33.34 Estimated cost this search

\$34.21 Estimated total session cost 1.833 DialUnits

?

Return to logon page!